Turoctocog alfa pegol

Drug Profile

Turoctocog alfa pegol

Alternative Names: Long acting recombinant factor VIII - Novo Nordisk; N8-GP; N8-GP rFVIII; NN-7088; NNC-0129-0000-1003; PEG turoctocog alfa; Pegylated turoctocog alfa; Recombinant factor VIII long acting - Novo Nordisk; rFVIII glycopegylated - Novo Nordisk

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Novo Nordisk
  • Class Antihaemorrhagics; Blood coagulation factors; Polyethylene glycols; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase III Haemophilia A

Most Recent Events

  • 20 Oct 2016 Phase-I clinical trials in Haemophilia A (In adolescents, In adults, In the elderly) in Germany (SC) (EudraCT2016-002396-99; NCT02994407)
  • 20 Oct 2016 Phase-I clinical trials in Haemophilia A (In adolescents, In adults, In the elderly) in Austria (SC) (EudraCT2016-002396-99)
  • 01 Oct 2016 Novo Nordisk initiates the phase I pathfinder™7 trial for Haemophilia A (In adolescents, In adults) in Denmark, Germany and the Netherlands (NCT02920398)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top